Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. on September 7, 2018, regarding an event that occurred on September 5, 2018. The filing discloses a partial exercise of a warrant by a non-operating subsidiary of the Registrant to purchase Series D Convertible Preferred Stock of Rafael Pharmaceuticals, Inc., a clinical-stage oncology-focused pharmaceutical company.
Key Financial Metrics
- Transaction Value: $10 million.
- Shares Purchased: 8.0 million shares of Rafael Pharmaceuticals' Series D Convertible Preferred Stock.
- Ownership Stake: The transaction represents approximately 7.9% of Rafael Pharmaceuticals' equity on a fully-diluted basis (excluding the remainder of the Warrant).
- Warrant Details: The Warrant is exercisable for up to 56% of Rafael Pharmaceuticals' equity. The right to exercise the first $10 million was held by CS Pharma Holdings, LLC (50% owned by IDT-Rafael Holdings, LLC, which is 90% owned by the Registrant).
Material Changes
The primary material change is the capital injection into Rafael Pharmaceuticals via the partial warrant exercise. The filing does not provide comparative financial data for Rafael Holdings, Inc. itself, nor does it detail changes in revenue, profit, or debt for the Registrant resulting from this specific transaction.
Outlook, Management Commentary, and Risks
Use of Proceeds: Rafael Pharmaceuticals intends to use the $10 million proceeds to pay expenses related to Phase III clinical trials of its flagship compound, CPI-613, as well as other trial phases, research, and general corporate purposes.
Regulatory Note: The information contained in this report, including the press release, is furnished pursuant to Item 7.01 and is not deemed "filed" with the SEC or incorporated by reference into other SEC filings.
Investor Verification Checklist
- Verify the current status and progress of the Phase III clinical trials for CPI-613.
- Confirm the total remaining value and exercise terms of the unexercised portion of the Warrant (up to 56% equity).
- Review the capital structure of Rafael Pharmaceuticals to understand the dilution impact of the Series D Convertible Preferred Stock.
- Assess the financial health of Rafael Holdings, Inc. separately from this subsidiary transaction, as this 8-K does not provide consolidated financial statements.